Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenoca

• 作 者: Zhu-Zeng Yin Zhi-Ming Zhao Wen
• 机 构: TheSecondDepartmentofHepatopancreatobiliarySurgery
• 出 处: 世界临床病例杂志
• 发表日期: 2020年13期
• 关键词: NAB-PACLITAXEL GEMCITABINE Pancreatic ductal adenocarcinoma Surgery ADJUVANT Res
• 基金项目: Supported by the China Postdoctoral Science Foundation,No.2015M582853.

BACKGROUND Nab-paclitaxel plus gemcitabine(AG)has resulted in higher tumor response and survival rates for metastatic or advanced pancreatic ductal adenocarcinoma(PDAC)compared with gemcitabine(GEM)alone.AIM To examine the feasibility and safety of AG adj